Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment
- PMID: 26216725
- DOI: 10.1007/s00270-015-1185-1
Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment
Abstract
Purpose: To evaluate in patients with hepatocellular carcinoma (HCC), whether assessment of tumor heterogeneity by histogram analysis of computed tomography (CT) perfusion helps predicting response to transarterial radioembolization (TARE).
Materials and methods: Sixteen patients (15 male; mean age 65 years; age range 47-80 years) with HCC underwent CT liver perfusion for treatment planning prior to TARE with Yttrium-90 microspheres. Arterial perfusion (AP) derived from CT perfusion was measured in the entire tumor volume, and heterogeneity was analyzed voxel-wise by histogram analysis. Response to TARE was evaluated on follow-up imaging (median follow-up, 129 days) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST). Results of histogram analysis and mean AP values of the tumor were compared between responders and non-responders. Receiver operating characteristics were calculated to determine the parameters' ability to discriminate responders from non-responders.
Results: According to mRECIST, 8 patients (50%) were responders and 8 (50%) non-responders. Comparing responders and non-responders, the 50th and 75th percentile of AP derived from histogram analysis was significantly different [AP 43.8/54.3 vs. 27.6/34.3 mL min(-1) 100 mL(-1)); p < 0.05], while the mean AP of HCCs (43.5 vs. 27.9 mL min(-1) 100 mL(-1); p > 0.05) was not. Further heterogeneity parameters from histogram analysis (skewness, coefficient of variation, and 25th percentile) did not differ between responders and non-responders (p > 0.05). If the cut-off for the 75th percentile was set to an AP of 37.5 mL min(-1) 100 mL(-1), therapy response could be predicted with a sensitivity of 88% (7/8) and specificity of 75% (6/8).
Conclusion: Voxel-wise histogram analysis of pretreatment CT perfusion indicating tumor heterogeneity of HCC improves the pretreatment prediction of response to TARE.
Keywords: Computed tomography perfusion; Hepatocellular carcinoma; Histogram analysis; Transarterial radioembolization; Treatment response.
Similar articles
-
Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases.Invest Radiol. 2013 Nov;48(11):787-94. doi: 10.1097/RLI.0b013e31829810f7. Invest Radiol. 2013. PMID: 23748229
-
Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion.J Vasc Interv Radiol. 2014 May;25(5):747-59. doi: 10.1016/j.jvir.2014.01.025. Epub 2014 Mar 13. J Vasc Interv Radiol. 2014. PMID: 24630751 Clinical Trial.
-
Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.Cardiovasc Intervent Radiol. 2018 Mar;41(3):459-465. doi: 10.1007/s00270-017-1826-7. Epub 2017 Oct 24. Cardiovasc Intervent Radiol. 2018. PMID: 29067511
-
Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.Hepatol Int. 2016 Nov;10(6):883-892. doi: 10.1007/s12072-016-9722-9. Epub 2016 Apr 28. Hepatol Int. 2016. PMID: 27126821 Review.
-
Radioembolization for the treatment of hepatocellular carcinoma.Clin Mol Hepatol. 2017 Jun;23(2):109-114. doi: 10.3350/cmh.2017.0004. Epub 2017 May 10. Clin Mol Hepatol. 2017. PMID: 28494530 Free PMC article. Review.
Cited by
-
A Systematic Review on the Role of the Perfusion Computed Tomography in Abdominal Cancer.Dose Response. 2021 Nov 24;19(4):15593258211056199. doi: 10.1177/15593258211056199. eCollection 2021 Oct-Dec. Dose Response. 2021. PMID: 34880716 Free PMC article. Review.
-
Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma.Aliment Pharmacol Ther. 2021 Oct;54(7):890-901. doi: 10.1111/apt.16563. Epub 2021 Aug 12. Aliment Pharmacol Ther. 2021. PMID: 34390014 Free PMC article. Review.
-
Artificial intelligence in assessment of hepatocellular carcinoma treatment response.Abdom Radiol (NY). 2021 Aug;46(8):3660-3671. doi: 10.1007/s00261-021-03056-1. Epub 2021 Mar 31. Abdom Radiol (NY). 2021. PMID: 33786653 Review.
-
Correlation of C-arm CT acquired parenchymal blood volume (PBV) with 99mTc-macroaggregated albumin (MAA) SPECT/CT for radioembolization work-up.PLoS One. 2020 Dec 30;15(12):e0244235. doi: 10.1371/journal.pone.0244235. eCollection 2020. PLoS One. 2020. PMID: 33378338 Free PMC article.
-
Assessment of Hepatocellular Carcinoma Response to 90Y Radioembolization Using Dynamic Contrast Material-enhanced MRI and Intravoxel Incoherent Motion Diffusion-weighted Imaging.Radiol Imaging Cancer. 2020 Jul 24;2(4):e190094. doi: 10.1148/rycan.2020190094. Radiol Imaging Cancer. 2020. PMID: 32803165 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous